Global Hereditary Angioedema Therapeutics Market Size & Outlook
Global hereditary angioedema therapeutics market, 2018-2030 (US$M)
Related Markets
Global hereditary angioedema therapeutics market highlights
- The global hereditary angioedema therapeutics market generated a revenue of USD 2,775.1 million in 2023 and is expected to reach USD 6,335.2 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 12.5% by 2030.
- In terms of segment, kallikrein inhibitor accounted for a revenue of USD 1,243.5 million in 2023.
- Kallikrein inhibitor is the most lucrative treatment segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Argentina is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 2,775.1 million |
| Market revenue in 2030 | USD 6,335.2 million |
| Growth rate | 12.5% (CAGR from 2023 to 2030) |
| Largest segment | Kallikrein inhibitor |
| Fastest growing segment | Kallikrein inhibitor |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Other key industry trends
- In terms of revenue, the North America accounted for 40.9% of the global hereditary angioedema therapeutics market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Argentina is the fastest growing regional market and is projected to reach USD 30.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Angioedema Therapeutics Market Scope
Hereditary Angioedema Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Attune Pharmaceuticals | View profile | 1-10 | New York, New York, United States, North America | http://attunepharma.com/ |
| Pharming Group | View profile | 382 | Darwinweg 24, Leiden, ZH, Netherlands, 2333 CR | https://www.pharming.com |
| KalVista Pharmaceuticals Inc | View profile | 118 | 55 Cambridge Parkway, Suite 901 East, Cambridge, MA, United States, 02142 | https://www.kalvista.com |
| Adverum Biotechnologies Inc | View profile | 121 | 100 Cardinal Way, Redwood CIty, CA, United States, 94063 | https://www.adverum.com |
| BioCryst Pharmaceuticals Inc | View profile | 531 | 4505 Emperor Boulevard, Suite 200, Durham, NC, United States, 27703 | https://www.biocryst.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
Global hereditary angioedema therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.81% in 2023. Horizon Databook has segmented the Global hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Hereditary Angioedema Therapeutics Treatment Outlook (Revenue, USD Million, 2018-2030)
- C1-esterase inhibitor
- Bradykinin B2 receptor antagonist
- Kallikrein inhibitor
- Others Treatment
- Global Hereditary Angioedema Therapeutics End Use Outlook (Revenue, USD Million, 2018-2030)
- Prophylaxis
- On-demand
- Global Hereditary Angioedema Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Intravenous
- Subcutaneous
- Oral
Reasons to subscribe to Global hereditary angioedema therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global hereditary angioedema therapeutics market databook
-
Our clientele includes a mix of hereditary angioedema therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global hereditary angioedema therapeutics market, including forecasts for subscribers. This global databook contains high-level insights into Global hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global hereditary angioedema hae therapeutics market size, by regions, 2018-2030 (US$M)
Top 10 countries: Hereditary angioedema hae therapeutics market size, 2023 (US$M)
Global hereditary angioedema hae therapeutics market share, by treatment, 2023 & 2030 (%, US$M)
Hereditary angioedema therapeutics market: Opportunity assessment by country
Global hereditary angioedema therapeutics market, by region, 2023 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
